Serum Levels of Insulin-Like Growth Factor 1, Interlukin-6, Heat-Shock Proteins-27 and Heat-Shock Proteins-60 as Inflammatory Markers of Type 2 Diabetes: A Case-Control Study

Abstract

Background: Inflammatory biomarkers such as insulin-like growth factor 1 (IGF-1), interleukin 6 (IL-6), and heat-shock proteins 27 (HSP-27) and 60 (HSP-60) may contribute to the development of type II diabetes mellitus. This study aimed to compare these inflammatory biomarkers among individuals with and without type II diabetes mellitus. Methods: This case-control study was conducted on fifty patients with type II diabetes mellitus and fifty individuals without it. None of the participants suffered from inflammatory diseases like rheumatoid arthritis and systemic lupus erythematosus. Patients in the diabetic group were matched with individuals in the non-diabetic group respecting their age and gender. Serum levels of IGF-1, IL-6, HSP-27, and HSP-60 were measured through enzyme-linked immunosorbent assay kits. Data were analyzed using the SPSS software (v. 15.0). Results: The mean serum levels of IGF-1, IL-6, HSP-27, and HSP-60 in the diabetic group were significantly greater than the nondiabetic group (P < 0.05). Conclusions: This study shows that IGF-1, IL-6, HSP-27, and HSP-60 inflammatory markers play roles in the development of type II diabetes mellitus.

Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy

“…As both T2DM and TNBC are inflammatory diseases, an in vitro study reported the important role of the pro-inflammatory IL-6 signaling in TNBC survival and aggressiveness, suggesting IL-6 inhibition as a potential therapeutic intervention and/or new adjuvant therapy to improve the clinical outcome of TNBC patients [50]. High levels of Hsp60 in the plasma and saliva of T2DM patients were detected compared to non-diabetic controls and immunohistochemical analysis in 66 TNBC tissues of Jordanian women that revealed that Hsp60, considered as an inflammatory marker of T2DM, was highly expressed in advanced stage of the tumor, considering Hsp60 as a poor prognosis marker in TNBC patients [51][52][53].…”